Can a liver drug help people with HIV? new trial aims to find out
NCT ID NCT07143968
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether resmetirom, a drug already approved for another liver condition, can safely reduce liver fat in people with HIV who also have fatty liver disease (MASLD). About 120 adults with well-controlled HIV will take either resmetirom or a placebo daily for 24 weeks. Researchers will measure changes in liver fat using MRI scans and track safety through blood tests and clinic visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
resmetirom
What this could lead to
If it works, this could point toward a treatment for fatty liver disease in people with HIV, a group often excluded from earlier studies.
What could go wrong
This is a small, early-phase trial (120 people) with a short 24-week treatment period. The drug may not reduce liver fat significantly, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Clinical Research Institute
NOT_YET_RECRUITINGWest Palm Beach, Florida, 33409, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke University Medical Center
NOT_YET_RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins University
NOT_YET_RECRUITINGBaltimore, Maryland, 21205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mt Sinai Health System
NOT_YET_RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UC San Diego Altman Clinical and Translational Research Institute
NOT_YET_RECRUITINGLa Jolla, California, 92037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UT Health Houston
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alabama Birmingham
NOT_YET_RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, San Francisco
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Commonwealth University
NOT_YET_RECRUITINGRichmond, Virginia, 23298, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact